In order to study whether LOFU-induced immune priming followed by ablative RT can induce anti-tumoral immunity and improve tumor control, we used a murine model of prostate cancer, TPSA23, grown either in wild-type male C57BL/6 mice, prostate specific antigen (PSA) transgenic mice24, or in immunodeficient athymic nude mice. The gene discussed is PROS1; the disease is prostate carcinoma.